## Professor Siyan ZHAN 詹思延教授

Dean, School of Public Health, Peking University 北京大學公共衛生學院院長

## Biography 講者介紹



Professor Zhan graduated from Beijing Medical University in 1986, now the Peking University Health Sciences Centre (PUHSC), and obtained postgraduate training in the Chinese University of Hong Kong. Her major is Epidemiology, especially pharmacoepidemiology.

Prof. Zhan is the Dean, School of Public Health, Peking University, the Director of Center for Clinical Epidemiology, Peking University Third Hospital. She is the member of IEA and ISPE, as well the Chairman of The Professional Committee of Pharmacoepidemiology of CPA and Chairman of China Epidemiology Association. She is also the editor-in-chief of *Chinese Journal of Pharmacoepidemiology* and deputy editor-in-chief of *Chinese Journal of Epidemiology*. As a principal investigator, Prof. Zhan has already completed many projects of drug safefy supported by the national natural science foundation of China (NSFC), CFDA and global fund. She has published more than 200 papers in pharmacoepidemiology field and won many national prizes. She is also the editor-in-chief, the current Textbook of Epidemiology, Textbook of Clinical Epidemiology and Textbook of Pharmacoepidemiology in China.

教育和工作經歷:北京醫科大學本科(6年制)和碩士、香港中文大學博士畢業。1989年碩士畢業後留校任教至今,2001年晉陞教授,2004年獲得博士生導師資格,2016年獲聘正高級專業技術二級崗位。目前擔任北京大學公共衛生學院院長、流行病與衛生統計學系主任,北京大學第三醫院臨床流行病學研究中心主任(雙聘),北京大學人工智慧研究院智慧公眾健康研究中心主任,北京大學循證醫學中心副主任,北京大學醫學部藥品上市後安全性研究中心主任。

目前擔任中國藥學會常務理事、藥物流行病學專委會主任委員;中華預防醫學會流行病學分會主任委員、公共衛生教育分會副主任委員、循證預防醫學專業委員會副主任委員;國務院學位委員會第八屆學科評議組(公共衛生與預防醫學)專家、國家食藥監局藥品註冊審評專家諮詢委員會(藥品安全及風險管理專家諮詢委員會)委員、國家免疫規劃專家諮詢委員會委員。擔任《藥物流行病學雜誌》主編、《中華流行病學雜誌》副主編、《Science Bulletin》醫學部副主編、《Pharmacoepidemiology & Drug Safety》編委和Associate Editor,《Clinical Epidemiology》編委等多家國內外雜誌編委;擔任《流行病學》統編教材第7版和第8版主編、長學制《臨床流行病學》第2、3版主編,《藥物流行病學》第2版聯合主編;主譯《循證醫學教學與實踐》、《藥物流行病學教程》、《觀察性療效比較研究的方案制定》。近年來承擔科技部、國自然等多項課題,作為第一完成人獲中華預防醫學會科學技術獎三等獎(2013)、中國藥學會科學技術三等獎(2013),北京市科技進步成果三等獎(2013)、華夏科技成果二等獎(2013)。 2016年獲第17屆吳階平 - 保羅楊森獎、2017年獲北京市優秀教師稱號、2020年北京市教工委優秀黨務工作者、2020年北京市抗擊新冠肺炎疫情先進個人、享受國務院政府特殊津貼;2021年作為教材主編獲首屆全國教材建設獎(二等獎)、寶鋼優秀教師特等獎提名獎。

## Abstract 題目摘要

Development and Practice of Vaccine Safety Active Surveillance Platform 疫苗安全性主動監測平台建設與實踐

Post-marketing active surveillance of vaccines safety can comprehensively and continuously collect adverse events after immunization, and timely detect and verify vaccine safety signals. It is not only an important supplement to AEFI, but also a necessary component of the WHO certification system. In the era of big data, active monitoring can be performed through longitudinal links to multi-source electronic medical databases, with rapid data transmission and regular updates, making it possible to detect vaccine safety signals in near real-time. The purpose of this presentation is to introduce the development status of post-marketing active surveillance of vaccine safety and relevant resources in China, explore platform construction and method optimization applicable to China, and share our experiences in China.

疫苗上市後安全性主動監測能夠全面、持續的收集免疫接種後不良事件,及時發現並驗證疫苗安全性信號,不僅是AEFI的重要補充,也是WHO認證體系的必要成分。隨著信息時代的到來,主動監測可通過縱向鏈接多源電子醫療數據庫開展分析,數據的快速傳輸與定期更新,使得接近實時的發現疫苗安全性信號成為可能。本講旨在介紹疫苗上市後安全性主動監測的發展現狀及我國相關資源,探索適用於我國的平台構建與方法優化,以期為我國開展相關工作提供思路。